BioCryst Selects Er-Kim Pharmaceuticals as Commercial Partner for ORLADEYO® (berotralstat) in Turkey
RESEARCH TRIANGLE PARK, N.C., July 19, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into a collaboration with Er-Kim Pharmaceuticals to commercialize ORLADEYO® (berotralstat) in Turkey. “We continue our mission to make ORLADEYO available to as many patients living with hereditary angioedema around the world as possible by partnering with companies that have deep expertise in commercializing rare disease therapies. We are pleased t